EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Dose-Dependent Silibinin Modulates Estrogen Receptor 1 and LINC RNA 00511 in Breast/Endometrial Cancer Cells

İbrahim Uğur Çalış, Esin Sakallı Çetin

European Journal of Therapeutics · 19.08.2026 · 32 (4) · 420-427

DOI: 10.58600/eurjther3011 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Therapeutics, online erschienen am 19.08.2026. Verfasst von İbrahim Uğur Çalış und 1 weiteren Autor:innen. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Muğla Sıtkı Koçman Üniversitesi.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Estrogen receptor–positive (ER+) breast and endometrial cancers are driven by estrogen-responsive transcriptional networks involving estrogen receptor 1 (ESR1) and regulatory long non-coding RNAs. We investigated the dose-dependent effects of silibinin on cell behavior and ESR1/long intergenic non-coding RNA 00511 (LINC00511) expression in ER+ cancer cell models.

Methods

MCF-7 breast cancer cells and Ishikawa endometrial cancer cells were exposed to graded concentrations of silibinin. Cell viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, wound closure by scratch (wound-healing) assay, and apoptosis by Annexin V/propidium iodide (PI) staining. ESR1 and LINC00511 transcript levels were quantified using reverse transcription quantitative polymerase chain reaction (RT-qPCR). Half-maximal inhibitory concentration (IC50) values were calculated from viability data.

Results

Lower silibinin concentrations increased cell viability and wound closure and were accompanied by higher ESR1 and LINC00511 expression. In contrast, higher concentrations suppressed ESR1 and LINC00511, reduced wound closure, and increased apoptosis. The IC50 values were 193 µM for MCF-7 cells and 263 µM for Ishikawa cells.

Conclusion

Silibinin elicited a biphasic, dose-dependent response in ER-positive breast and endometrial cancer cells. These findings suggest that the biological effects of silibinin in ER-positive tumor models should be interpreted in a dose-dependent context.

Förderung

  • Muğla Sıtkı Koçman Üniversitesi

Zitieren

APA

Çalış, İ. U., & Çetin, E. S. (2026). Dose-Dependent Silibinin Modulates Estrogen Receptor 1 and LINC RNA 00511 in Breast/Endometrial Cancer Cells. European Journal of Therapeutics, 32(4), 420-427. https://doi.org/10.58600/eurjther3011

Vancouver

Çalış İU, Çetin ES. Dose-Dependent Silibinin Modulates Estrogen Receptor 1 and LINC RNA 00511 in Breast/Endometrial Cancer Cells. European Journal of Therapeutics. 2026;32(4):420-427. doi:10.58600/eurjther3011

BibTeX
@article{al2026,
  author = {Çalış, İbrahim Uğur and Çetin, Esin Sakallı},
  title = {Dose-Dependent Silibinin Modulates Estrogen Receptor 1 and LINC RNA 00511 in Breast/Endometrial Cancer Cells},
  journal = {European Journal of Therapeutics},
  year = {2026},
  volume = {32},
  number = {4},
  pages = {420--427},
  doi = {10.58600/eurjther3011}
}
Kostenlos starten →